Home/Indications/Oncology/Chronic lymphocytic leukemia

Chronic lymphocytic leukemia

Oncology 7 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Oncology indication. Chronic lymphocytic leukemia has 7 FDA-approved novel treatments, led by Roche across 7 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Chronic lymphocytic leukemia Market Leaders

Companies with the most FDA-approved novel Chronic lymphocytic leukemia drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

Pirtobrutinib

Loxo Oncology, Inc.

Estimated · fresh NCT04965493

Q4 2026

Ibrutinib

Johnson & Johnson

Estimated · fresh NCT01804686

Q1 2027

Acalabrutinib

Acerta Pharma BV

Estimated · stale NCT03836261

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Chronic lymphocytic leukemia Treatments by Mechanism

Top 10 mechanisms across 77 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

46 trials 18 active 8 sponsors

BCL-2 Inhibitor

10 trials 5 active 3 sponsors

CD20-directed Cytolytic Antibody

9 trials 1 active 7 sponsors

Thalidomide Analog

3 trials 1 sponsor

PI3K-delta/PI3K-gamma

3 trials 2 sponsors

Alkylating Drug

2 trials 2 sponsors

CD52-directed Cytolytic Antibody

1 trials 1 sponsor

Hematopoietic Stem Cell Mobilizer

1 trials 1 sponsor

CD19

1 trials 1 sponsor

ABL kinase/BCR-ABL/EPHA2/FYN/LCK/PDGFRβ/SRC/YES/c-KIT

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Chronic lymphocytic leukemia Clinical Pipeline by Phase

290 industry-sponsored trials across 114 sponsors

Showing 4 of 4 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2030-05	NCT07218341
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2030-05	NCT06876662
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2030-05	NCT06876649
AstraZeneca	Acalabrutinib capsule	—	COMPLETED	2023-05-02	NCT04930536

Showing 57 of 57 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	RECRUITING	2026-12-31	NCT01804686
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2027-10	NCT05254743
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2028-03	NCT06428019
BeOne Medicines	BGB-16673	—	RECRUITING	2028-04-17	NCT06973187
BeOne Medicines	BGB-16673	—	RECRUITING	2028-05-15	NCT06846671
Dizal Pharmaceuticals	DZD8586	—	RECRUITING	2029-01	NCT07139873
BeOne Medicines	Sonrotoclax	—	RECRUITING	2029-09-30	NCT06943872
Newave Pharmaceutical Inc	Rocbrutinib	—	RECRUITING	2029-10-30	NCT07342478
BeOne Medicines	BGB-16673	—	RECRUITING	2029-11-30	NCT06970743
BeOne Medicines	Sonrotoclax	—	RECRUITING	2031-02	NCT07277231
Merck	Nemtabrutinib	—	RECRUITING	2032-06-01	NCT05947851
Merck	Nemtabrutinib	—	RECRUITING	2032-09-07	NCT06136559
Grifols Therapeutics LLC	Xembify	—	RECRUITING	2026-05	NCT05645107
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-10	NCT04965493
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-01-31	NCT03836261
Merck	Nemtabrutinib	—	ACTIVE NOT RECRUITING	2027-05-19	NCT05624554
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-07-15	NCT05057494
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-08	NCT03844048
BeOne Medicines	Sonrotoclax	—	ACTIVE NOT RECRUITING	2032-02	NCT06073821
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2025-07-11	NCT05023980
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-01-03	NCT04075292
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2023-08-29	NCT04666038
Acerta Pharma BV	Acalabrutinib (ACP-196)	—	ACTIVE NOT RECRUITING	2021-09-03	NCT02970318
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-05-07	NCT03336333
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2020-09-15	NCT02477696
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2019-02-08	NCT02475681
Nurix Therapeutics, Inc.	NX-5948	—	NOT YET RECRUITING	2029-10	NCT07516093
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2025-11-04	NCT04008706
Octapharma	Panzyga	—	COMPLETED	2025-09-19	NCT04502030
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2024-03-19	NCT04285567
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2023-08-18	NCT01724346
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2022-08-08	NCT03734016
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2021-12-29	NCT02980731
AbbVie	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2021-10-12	NCT03406156
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2020-10-27	NCT00774345
SecuraBio	IPI-145	—	COMPLETED	2020-06-12	NCT02049515
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2020-04-01	NCT02301156
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2019-06-10	NCT01569295
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2019-04-10	NCT02756611
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2019-01-23	NCT01611090
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2018-03-26	NCT02264574
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	COMPLETED	2017-05-19	NCT02004522
Roche	Bendamustine	—	COMPLETED	2017-05-08	NCT02005471
Roche	Bendamustine	—	COMPLETED	2016-12-29	NCT01905943
Johnson & Johnson	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2015-12-01	NCT01973387
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2015-05	NCT01722487
Merck	Dinaciclib	—	COMPLETED	2014-12	NCT01580228
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2014-03-31	NCT00910910
Pharmacyclics LLC.	ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-11	NCT01578707
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2013-10	NCT01539512
Lundbeck Canada Inc.	Bendamustine at a dose of 100 mg/m2	—	COMPLETED	2013-06	NCT01500083
TG Therapeutics, Inc.	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	TERMINATED	2023-02-22	NCT02612311
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-12-20	NCT03801525
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2018-08-15	NCT01659021
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2018-05-21	NCT01539291
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2016-05-30	NCT01980888
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2016-05-13	NCT01980875

Showing 100 of 116 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Vector Vitale LLC	Zinc-64 Aspartate	—	RECRUITING	2026-07-31	NCT06506643
BeOne Medicines	BGB-16673	—	RECRUITING	2026-11	NCT05006716
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2026-11	NCT04895436
Ascentage Pharma Group Inc.	APG2575	—	RECRUITING	2026-12	NCT05147467
Vironexis Biotherapeutics Inc.	—	—	RECRUITING	2027-06	NCT06533579
Dizal Pharmaceuticals	DZD8586	—	RECRUITING	2027-09	NCT06539182
Curis, Inc.	Emavusertib	—	RECRUITING	2027-11	NCT07271667
Nurix Therapeutics, Inc.	NX-5948	—	RECRUITING	2028-01	NCT07221500
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2028-06	NCT06588478
BeiGene	BGB-16673	—	RECRUITING	2029-01-31	NCT05294731
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	RECRUITING	2029-05	NCT02966756
BeOne Medicines	Sonrotoclax	—	RECRUITING	2029-11-30	NCT06697184
Dizal Pharmaceuticals	DZD8586	—	RECRUITING	2029-12	NCT07154264
CRISPR Therapeutics AG	CTX112	—	RECRUITING	2030-01	NCT05643742
Ossium Health, Inc.	—	—	RECRUITING	2026-05-31	NCT05589896
IDP Discovery Pharma S.L.	IDP-121	—	RECRUITING	2025-12-22	NCT05908409
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB3909 tablet	—	RECRUITING	2025-12	NCT05959694
Ascentage Pharma Group Inc.	APG-2575	—	RECRUITING	2024-10-20	NCT04494503
Roche	Venetoclax	BCL-2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-10-31	NCT06524375
BeOne Medicines	Sonrotoclax	—	ACTIVE NOT RECRUITING	2026-11	NCT06637501
Novartis	Rapcabtagene autoleucel single agent	—	ACTIVE NOT RECRUITING	2027-06-30	NCT03960840
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	Nemtabrutinib	—	ACTIVE NOT RECRUITING	2027-09-17	NCT03162536
Genmab	Epcoritamab	—	ACTIVE NOT RECRUITING	2027-12	NCT04623541
Allogene Therapeutics	ALLO-647	—	ACTIVE NOT RECRUITING	2029-02	NCT04416984
Merck	Zilovertamab vedotin	—	ACTIVE NOT RECRUITING	2029-05-17	NCT05458297
Cellectar Biosciences, Inc.	Iopofosine I 131 single dose	—	ACTIVE NOT RECRUITING	2026-06-22	NCT02952508
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-035	—	ACTIVE NOT RECRUITING	2025-12	NCT05944978
BeiGene	BGB-11417	—	ACTIVE NOT RECRUITING	2025-01-24	NCT05479994
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2022-12-22	NCT03932331
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-07-15	NCT02029443
Acerta Pharma BV	ACP-196 (acalabrutinib)	—	ACTIVE NOT RECRUITING	2020-10-16	NCT02717611
Guangzhou Lupeng Pharmaceutical Company LTD.	Lacutoclax	—	NOT YET RECRUITING	2028-03-30	NCT07609823
MingSight Pharmaceuticals, Inc	MS-553, DS1	—	NOT YET RECRUITING	2028-09	NCT06979076
AstraZeneca	Acalabrutinib	Kinase Inhibitor [EPC]	NOT YET RECRUITING	2029-05-01	NCT07024706
Guangzhou Lupeng Pharmaceutical Company LTD.	Lacutoclax+Rocbrutinib	—	NOT YET RECRUITING	2029-06-30	NCT07609862
Nurix Therapeutics, Inc.	NX-5948	—	NOT YET RECRUITING	2033-05	NCT07520006
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2026-01-09	NCT04116437
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2025-10-09	NCT05105841
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	COMPLETED	2025-01-27	NCT03740529
Cyteir Therapeutics, Inc.	CYT-0851	—	COMPLETED	2024-11-30	NCT03997968
Oncternal Therapeutics, Inc	Cirmtuzumab (2-16 kg/mg) plus Ibrutinib	—	COMPLETED	2024-09-25	NCT03088878
BeiGene	BGB-10188	—	COMPLETED	2024-08-28	NCT04282018
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2021-12-22	NCT02141282
Precision BioSciences, Inc.	Fludarabine	—	COMPLETED	2021-06-24	NCT04030195
AbbVie	azacitadine	—	COMPLETED	2021-03-12	NCT02265731
AstraZeneca	Cerdulatinib	—	COMPLETED	2020-12-15	NCT01994382
Pharmacyclics LLC.	ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-11-12	NCT02910583
AbbVie	ABT-199 (Main Cohort)	—	COMPLETED	2020-10-28	NCT01889186
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-07-14	NCT02362035
Acerta Pharma BV	Acalabrutinib (Arm A)	—	COMPLETED	2020-06-26	NCT02337829
Gilead	Tirabrutinib	—	COMPLETED	2019-06-17	NCT02968563
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2019-04-26	NCT01109069
Gilead	Tirabrutinib	—	COMPLETED	2019-02-20	NCT02983617
Roche	bendamustine	—	COMPLETED	2018-11-19	NCT02071225
MorphoSys AG	Tafasitamab	—	COMPLETED	2018-11	NCT02639910
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2018-06-15	NCT03206918
Bristol-Myers Squibb	lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2017-09-05	NCT00963105
Roche	Bendamustine	—	COMPLETED	2016-11-07	NCT02320487
Novartis	HSC835	—	COMPLETED	2016-10-03	NCT01474681
Novartis	HSC835	—	COMPLETED	2016-08-29	NCT01930162
MedImmune LLC	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2016-01-08	NCT01466153
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2015-12	NCT02013128
Polyphor Ltd.	POL6326	—	COMPLETED	2015-11	NCT01413568
SymBio Pharmaceuticals	SyB L-0501	—	COMPLETED	2015-06	NCT02042911
TG Therapeutics, Inc.	Ublituximab	—	COMPLETED	2015-05	NCT01647971
Aptevo Therapeutics	TRU-016 and bendamustine	—	COMPLETED	2014-12	NCT01188681
TME Pharma AG	NOX-A12	—	COMPLETED	2014-11	NCT01486797
Pharmacyclics LLC.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2014-06	NCT01744691
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2014-01	NCT01868893
AbbVie (prior sponsor, Abbott)	Navitoclax	—	COMPLETED	2013-07	NCT01557777
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2013-06	NCT01217749
Jiangsu Simcere Pharmaceutical Co., Ltd.	Bendamustine hydrochloride injection	—	COMPLETED	2013-06	NCT01109264
MedImmune LLC	CAT-8015 20 mcg/kg	—	COMPLETED	2013-03-04	NCT01030536
Gilead	veltuzumab	—	COMPLETED	2013-03	NCT00546793
Novartis	Ofatumumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-02	NCT01520922
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2012-12	NCT01105247
Roche	ABT-263	—	COMPLETED	2012-06	NCT01087151
CytRx	bafetinib	—	COMPLETED	2011-12	NCT01144260
BioCryst Pharmaceuticals	forodesine HCl	—	COMPLETED	2010-11	NCT00640523
Zhejiang DTRM Biopharma	DTRM-555	—	TERMINATED	2024-12-31	NCT04305444
Incyte Corporation	tafasitamab	—	TERMINATED	2024-10-22	NCT04809467
MingSight Pharmaceuticals, Inc	MS-553	—	TERMINATED	2023-11-28	NCT03492125
MingSight Pharmaceuticals, Inc	MS-553	—	TERMINATED	2023-11-28	NCT05720052
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQ-B3525 tablets	—	TERMINATED	2023-11-22	NCT04808570
Genmab	GEN3009	—	TERMINATED	2022-11-21	NCT04358458
Hangzhou Zenshine Pharmaceuticals Co., Ltd.	ZX-101A	—	TERMINATED	2022-07-08	NCT04504708
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-05-26	NCT02656303
TG Therapeutics, Inc.	Venetoclax	BCL-2 Inhibitor [EPC]	TERMINATED	2022-05-26	NCT03379051
TG Therapeutics, Inc.	TGR-1202	—	TERMINATED	2022-05-25	NCT03207256
TG Therapeutics, Inc.	Ublituximab	—	TERMINATED	2022-05-22	NCT04016805
Aprea Therapeutics	APR-246 (eprenetapopt) + Acalabrutinib in CLL	—	TERMINATED	2021-08-23	NCT04419389
TG Therapeutics, Inc.	Umbralisib	—	TERMINATED	2021-06-10	NCT02742090
Sunesis Pharmaceuticals	SNS-062	—	TERMINATED	2020-08-31	NCT03037645
Sumitomo Pharma America, Inc.	TP-0903	—	TERMINATED	2020-01-21	NCT03572634
Innate Pharma	monalizumab	—	TERMINATED	2018-10-29	NCT02557516
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2018-06-18	NCT01090414
Asana BioSciences	ASN002 Dose Escalation	—	TERMINATED	2018-06	NCT02440685
Gilead	Entospletinib MM	—	TERMINATED	2017-09-14	NCT01799889
Gilead	hLL1-DOX (IMMU-115)	—	TERMINATED	2016-11	NCT01585688
Gilead	Idelalisib	Kinase Inhibitor [EPC]	TERMINATED	2016-04-27	NCT02044822

Showing 100 of 113 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Newave Pharmaceutical Inc	LP-118	—	RECRUITING	2026-12-31	NCT04771572
Nurix Therapeutics, Inc.	NX-5948	—	RECRUITING	2027-01	NCT05131022
AbbVie	ABBV-319	—	RECRUITING	2027-02	NCT05512390
Imugene Limited	Azer-cel	—	RECRUITING	2027-06	NCT03666000
Carna Biosciences, Inc.	Docirbrutinib	—	RECRUITING	2027-09	NCT05602363
Schrödinger, Inc.	SGR-1505	—	RECRUITING	2027-11	NCT05544019
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS73565	—	RECRUITING	2028-06	NCT06980116
Ono Pharmaceutical Co., Ltd.	ONO-4685	—	RECRUITING	2029-01-31	NCT06547528
Umoja Biopharma	rapamycin	—	RECRUITING	2029-03	NCT06528301
Roche	Mosunetuzumab	—	RECRUITING	2031-02-10	NCT05091424
Nurix Therapeutics, Inc.	NX-2127	—	RECRUITING	2026-05	NCT04830137
Lomond Therapeutics Holdings, Inc.	ZE 50-0134	—	RECRUITING	2026-03	NCT06708897
CytoCares Inc	CC312	—	RECRUITING	2026-03	NCT06037018
AbbVie	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2027-07	NCT06291220
AbbVie	ABBV-525	—	ACTIVE NOT RECRUITING	2029-07	NCT05618028
Miltenyi Biomedicine GmbH	MB-CART19.1	—	ACTIVE NOT RECRUITING	2026-06	NCT03853616
BeOne Medicines	BGB-21447	—	ACTIVE NOT RECRUITING	2026-05	NCT05828589
Sana Biotechnology	SC291	—	ACTIVE NOT RECRUITING	2025-11-04	NCT05878184
Fate Therapeutics	FT819	—	ACTIVE NOT RECRUITING	2025-06-18	NCT04629729
Bio-Path Holdings, Inc.	L-Bcl-2 antisense oligonucleotide	—	ACTIVE NOT RECRUITING	2025-04	NCT04072458
Nkarta, Inc.	NKX019	—	ACTIVE NOT RECRUITING	2025-03-31	NCT05020678
Ascentage Pharma Group Inc.	APG-2575	—	ACTIVE NOT RECRUITING	2024-10-20	NCT03913949
Fochon Pharmaceuticals, Ltd.	FCN-338	—	ACTIVE NOT RECRUITING	2024-04-28	NCT04682808
Acerta Pharma BV	Ceralasertib	—	ACTIVE NOT RECRUITING	2021-09-07	NCT03328273
Acerta Pharma BV	acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2020-07-20	NCT02157324
Ascentage Pharma Group Inc.	APG-3288	—	NOT YET RECRUITING	2029-12	NCT07424833
Regeneron	Odronextamab multiple dose levels	—	COMPLETED	2025-08-21	NCT02290951
Prelude Therapeutics	PRT2527	—	COMPLETED	2025-06-12	NCT05665530
Johnson & Johnson	JNJ-64264681	—	COMPLETED	2025-01-16	NCT04657224
Iovance Biotherapeutics, Inc.	IOV-2001	—	COMPLETED	2024-11-11	NCT04155710
Xencor, Inc.	XmAb13676	—	COMPLETED	2024-04	NCT02924402
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Zilovertamab vedotin	—	COMPLETED	2023-12-18	NCT03833180
Boryung Pharmaceutical Co., Ltd	BR101801 (Phase Ia)	—	COMPLETED	2023-09-21	NCT04018248
Cyclacel Pharmaceuticals, Inc.	CYC065	—	COMPLETED	2022-11-15	NCT03739554
AbbVie	ABT-199	—	COMPLETED	2022-06-23	NCT01682616
TG Therapeutics, Inc.	Umbralisib	—	COMPLETED	2021-11-04	NCT02535286
AstraZeneca	AZD4573	—	COMPLETED	2021-09-30	NCT03263637
Acerta Pharma BV	acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2021-08-20	NCT02296918
Bristol-Myers Squibb	CC-115	—	COMPLETED	2021-03-12	NCT01353625
Zhejiang DTRM Biopharma	DTRMWXHS-12	—	COMPLETED	2020-11-23	NCT02900716
miRagen Therapeutics, Inc.	Cobomarsen	—	COMPLETED	2020-10-06	NCT02580552
AbbVie	ABT-199	—	COMPLETED	2020-05-08	NCT01328626
TG Therapeutics, Inc.	Ublituximab + TGR-1202	—	COMPLETED	2019-10	NCT02006485
ADC Therapeutics S.A.	ADCT-402	—	COMPLETED	2019-02-21	NCT02669017
Zhejiang DTRM Biopharma	DTRMWXHS-12	—	COMPLETED	2019-02	NCT02891590
Roche	Bendamustine	—	COMPLETED	2018-08-17	NCT01671904
TG Therapeutics, Inc.	TGR-1202	—	COMPLETED	2018-02	NCT01767766
TG Therapeutics, Inc.	TGR-1202 + Obinutuzumab + Chlorambucil	—	COMPLETED	2017-11	NCT02100852
Merck KGaA, Darmstadt, Germany	MSC2490484A (M3814)	—	COMPLETED	2017-06-29	NCT02316197
Millennium Pharmaceuticals, Inc.	Alisertib	—	COMPLETED	2016-10-01	NCT00697346
ImmunoGen, Inc.	IMGN529	—	COMPLETED	2016-07	NCT01534715
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2016-06-24	NCT02381080
Celldex Therapeutics	CDX-1127	—	COMPLETED	2015-12	NCT01460134
Tragara Pharmaceuticals, Inc.	TG02 citrate	—	COMPLETED	2015-07	NCT01699152
Bristol-Myers Squibb	AVL-292	—	COMPLETED	2015-06-26	NCT01351935
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2015-04-28	NCT01088048
Roche	DCDT2980S	—	COMPLETED	2015-03	NCT01209130
Gilead	Idelalisib	Kinase Inhibitor [EPC]	COMPLETED	2014-12-25	NCT02242045
Traws Pharma, Inc.	ON 01910.Na	—	COMPLETED	2014-11	NCT00854646
Bristol-Myers Squibb	BMS-936564 (Anti-CXCR4)	—	COMPLETED	2014-11	NCT01120457
Sanofi	SAR245409	—	COMPLETED	2014-05	NCT01410513
Pfizer	BMN 673	—	COMPLETED	2014-03-31	NCT01399840
Amgen	AMG 319	—	COMPLETED	2013-10	NCT01300026
Fate Therapeutics	Single FT1050 treated UCB unit	—	COMPLETED	2013-10	NCT01527838
Merck	Dinaciclib	—	COMPLETED	2013-10	NCT01650727
Threshold Pharmaceuticals	TH-302	—	COMPLETED	2013-08	NCT01149915
Gilead	Treatment A	—	COMPLETED	2013-08	NCT01841489
AbbVie (prior sponsor, Abbott)	ABT-348	—	COMPLETED	2013-06	NCT01110473
AbbVie (prior sponsor, Abbott)	ABT-263	—	COMPLETED	2013-05	NCT00868413
Xencor, Inc.	XmAb5574	—	COMPLETED	2013-01	NCT01161511
American Regent, Inc.	Luitpold Azacitidine	—	COMPLETED	2012-12	NCT01290302
Pharmacyclics LLC.	PCI-32765	—	COMPLETED	2012-11	NCT01292135
Millennium Pharmaceuticals, Inc.	TAK-901	—	COMPLETED	2012-09	NCT00807677
Roche	Polatuzumab Vedotin	—	COMPLETED	2012-06-29	NCT01290549
Aptevo Therapeutics	TRU-016 (anti-CD37 protein therapeutic)	—	COMPLETED	2011-12	NCT00614042
Gilead	CAL-101	—	COMPLETED	2011-12	NCT00710528
Tesaro, Inc.	MK-4827	—	COMPLETED	2011-09	NCT00749502
Laboratoire français de Fractionnement et de Biotechnologies	LFB-R603	—	COMPLETED	2011-08	NCT01098188
AbbVie	navitoclax	—	COMPLETED	2011-05	NCT01121133
Memgen, LLC	ISF35	—	COMPLETED	2011-04	NCT00772486
Genzyme, a Sanofi Company	plerixafor	Hematopoietic Stem Cell Mobilizer [EPC]	COMPLETED	2010-11	NCT00694590
Abbott	ABT-263	—	COMPLETED	2010-10	NCT01021358
Abbott	ABT-263	—	COMPLETED	2010-08	NCT00743028
Bristol-Myers Squibb	MDX-1342	—	COMPLETED	2010-05	NCT00593944
Biomea Fusion Inc.	BMF-219	—	TERMINATED	2025-02-13	NCT05153330
IGM Biosciences, Inc.	Aplitabart (IGM-8444)	—	TERMINATED	2025-01-20	NCT04553692
Novartis	JBH492	—	TERMINATED	2024-09-05	NCT04240704
MEI Pharma, Inc.	voruciclib monotherapy	—	TERMINATED	2024-07-24	NCT03547115
TG Therapeutics, Inc.	TG-1801	—	TERMINATED	2024-06-12	NCT04806035
TG Therapeutics, Inc.	TG-1701	—	TERMINATED	2024-05-21	NCT03671590
Aptose Biosciences Inc.	CG-806	—	TERMINATED	2024-05-17	NCT03893682
Prelude Therapeutics	PRT1419	—	TERMINATED	2024-01-19	NCT05107856
Novartis	VAY736	—	TERMINATED	2023-09-29	NCT03400176
Fate Therapeutics	FT596	—	TERMINATED	2023-09-27	NCT04245722
Lava Therapeutics	LAVA-051	—	TERMINATED	2023-09-06	NCT04887259
Vincerx Pharma, Inc.	VIP152	—	TERMINATED	2023-05-26	NCT04978779
MEI Pharma, Inc.	ME-401	—	TERMINATED	2023-03-29	NCT02914938
Exelixis	XL114	—	TERMINATED	2022-11-01	NCT05144347
Kite, A Gilead Company	brexucabtagene autoleucel	CD19	TERMINATED	2021-02-12	NCT03624036
Tarix Pharmaceuticals	TXA127 300 mcg/kg/day	—	TERMINATED	2020-12	NCT01300611

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Chronic lymphocytic leukemia

BTK (5)

Novel Chronic lymphocytic leukemia Drugs by Company (New molecular entities)

6 companies have an FDA-approved novel drug for Chronic lymphocytic leukemia.

Roche 2 drugs

BEONE MEDICINES USA 1 drug

SECURA 1 drug

LOXO ONCOL 1 drug

WAYLIS THERAP 1 drug

Juno Therapeutics, Inc. a Bristol Myer-Squibb Company 1 drug

Breyanzi

lisocabtagene maraleucel

BLA 2021

Reformulations (8 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Chronic lymphocytic leukemia Drug Targets

Molecular targets of approved and investigational Chronic lymphocytic leukemia drugs — 7 targets tracked.

CD20 6 BTK 3 PI3Kδ 2 Hyaluronan 1 PI3K-delta 1 PI3K-gamma 1 CD19 1

Biosimilars (3 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

2018

Generic Drugs (1 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

IDELALISIB